Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

Repligen Corporation. "Our financial resources will allow us to continue to advance our clinical programs and aggressively pursue the acquisition of new product candidates for our pipeline in 2009."

For the nine-month period ended December 31, 2008, total revenue was $24,768,000 compared to $15,996,000 for the same period in fiscal year 2008. Operating expenses for the nine-month period were $17,672,000, compared to $16,409,000, exclusive of the net gain of $40,170,000 from a litigation settlement, for the same period in fiscal year 2008. Net income for the nine-month period was $8,439,000 or $0.27 per diluted share compared to net income of $40,304,000 or $1.29 per diluted share in the same period in fiscal year 2008.

Corporate Update

RG1068 for Imaging of the Pancreas

We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, designed to assess the ability of RG1068 enhanced magnetic resonance imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment of diseases such as acute and chronic pancreatitis. This study is being conducted at approximately 25 clinical sites within the U.S. and Canada and will enroll approximately 250 patients. The FDA has granted this program Fast Track Designation, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. There are more than 300,000 procedures conducted in the U.S. and Europe each year that may benefit from enhancement with RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... of the "Global Lactic Acid  (Biodegradable Polymer, ... - Trends & Forecasts to 2019" report ... the simplest hydroxyl-carboxylic acid with an asymmetrical carbon ... in the biodegradable polymer, food and beverage, personal ...
(Date:8/27/2014)... 2014  Lisa Kulik saw fireworks for the first ... thanks to a groundbreaking retinal implant co-invented by ... at the University of Southern California (USC) Eye Institute. ... Ariz. resident who has retinitis pigmentosa, a ... On June 2, she became the first person west ...
Breaking Biology Technology:Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5
... Calif., Oct. 26 iDiverse announced that it has ... number of lethal stresses normally encountered in the bioproduction ... the yeast to generate significantly more ethanol. ... proof-of-concept technology and are rapidly developing a 2nd generation ...
... a microwave oven, the fundamental nanotechnology process of ... use to make the ubiquitous semi-conductor chips. By ... Nanotechnology (NINT) and the University of Alberta have ... molecular self-assembly process used to assemble block copolymers, ...
... BSI Announces Global Launch of Clinical Strategy Review for CE Marking -- RESTON, Virginia, October 25, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Biology Technology:iDiverse Develops Stress Resistant Yeast for Producing Fuel Ethanol 2BSI Announces Global Launch of Clinical Strategy Review for CE Marking 2BSI Announces Global Launch of Clinical Strategy Review for CE Marking 3BSI Announces Global Launch of Clinical Strategy Review for CE Marking 4BSI Announces Global Launch of Clinical Strategy Review for CE Marking 5BSI Announces Global Launch of Clinical Strategy Review for CE Marking 6BSI Announces Global Launch of Clinical Strategy Review for CE Marking 7BSI Announces Global Launch of Clinical Strategy Review for CE Marking 8BSI Announces Global Launch of Clinical Strategy Review for CE Marking 9
(Date:8/27/2014)... getting effective doses of the HIV drug maraviroc, a ... studies, completed before the drug was licensed in 2007, ... is key to removing maraviroc from the body. The ... the protein including nearly half of African-Americans ... to those who lack the protein even when given ...
(Date:8/27/2014)... when it only requires nerve cells to rearrange existing ... to generate new patterns, a study of monkeys has ... through recordings of electrical activity of brain cell networks. ... of Health. , "We looked into the brain and ... outside the box," said Aaron Batista, Ph.D., an assistant ...
(Date:8/27/2014)... new skill is easier when it is related to ... pianist might learn a new melody more easily than ... engineers from the Center for the Neural Basis of ... and Carnegie Mellon Universityhave discovered a fundamental constraint in ... as the cover story in the Aug. 28, 2014, ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2Scientists plug into a learning brain 2Scientists plug into a learning brain 3Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3
... University School of Medicine (BUSM) report that physicians who use ... on patients with an abnormal Pap test could increase the ... achieve resolution in less time than using traditional methods. These ... . Screening for cervical cancer with a Pap ...
... the University of North Carolina at Chapel Hill School of ... the collateral circulation the "back-up" blood vessels that can ... heart attack or stroke. The new knowledge could help ... drugs or procedures that can cause new collaterals to ...
... oil and methane leaked into the Gulf of Mexico suggests ... the source of the pollution. The research investigates five scenarios ... an estimated rate of flow from the Deepwater Horizon spill, ... April to mid July of this year. A ...
Cached Biology News:Electronic tracking system can improve follow-up after an abnormal Pap test 2Genetics underlie formation of body's back-up bypass vessels 2Deep plumes of oil could cause dead zones in the Gulf 2
... (GR) Competitor Assay Kits are ideal for ... The PolarScreen GR Competitor Assay Kits contain ... and one of the following proprietary fluorescent ... GS Red (red assay kit), or GS ...
McCoy's 5A Medium. Without Tryptose or Phosphate Broth. Contains Sodium Bicarbonate....
... pathway is the major proteolytic system ... where it catalyzes the selective degradation ... rapid elimination of proteins with abnormal ... 1996). The critical protease in this ...
... to RFC1 Immunogen Recombinant protein corresponding ... C expressed in E. coli. Reactivity / ... Not yet tested in other species. This antibody ... Background Information Replication factor C is a ...
Biology Products: